Out-licensing
Up-to-date access to technology licensing opportunities worldwide.
- Out-licensing
- Browse
Licensing opportunities
KD501 is a partially purified extract from Scrophulariae Radix, which shows an efficacy for the treatment of strokes and degenerated neuronal disease in vivo. Elcom filed an IND application with the KFDA (The Korea Food & Drug Administration) in May More
Related Reports
Market Research Reports provided by reports.iptechex.com
Feb 2011 - 4 pages - $100
Oct 2010 - 53 pages - $1,000
Jun 2006 - 1068 pages - $2,495
Feb 2011 - 75 pages - $1,000
May 2011 - 25 pages - $250
Jun 2011 - 113 pages - $3,835
Aug 2011 - 8 pages - $75
Aug 2011 - 7 pages - $75
Sep 2011 - 97 pages - $3,500
Apr 2010 - 510 pages - $2,695
Your selection
Browse By
© Copyright 1998-2013 IP Technology Exchange, Inc All rights reserved. Terms and Conditions | Contact us